{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T02:07:11Z","timestamp":1777860431225,"version":"3.51.4"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1097\/jcma.0000000000000071","type":"journal-article","created":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T21:33:07Z","timestamp":1553549587000},"page":"375-380","source":"Crossref","is-referenced-by-count":10,"title":["The T-SPOT.TB assay used for screening and monitoring of latent tuberculosis infection in patients with Beh\u00e7et\u2019s disease pre- and post-anti-TNF treatment"],"prefix":"10.1097","volume":"82","author":[{"given":"Yan","family":"Shen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai-Fen","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Long","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-7-20210129","first-page":"431","article-title":"Behcet\u2019s syndrome--eventually.","volume":"9","author":"Franks","year":"1998","journal-title":"Int J STD AIDS"},{"key":"R2-7-20210129","first-page":"1362","article-title":"Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet\u2019s disease with refractory uveoretinitis.","volume":"31","author":"Ohno","year":"2004","journal-title":"J Rheumatol"},{"key":"R3-7-20210129","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1136\/gut.49.5.725","article-title":"Treatment of intestinal Behcet\u2019s syndrome with chimeric tumor necrosis factor alpha antibody.","volume":"49","author":"Travis","year":"2001","journal-title":"Gut"},{"key":"R4-7-20210129","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/ibd.20457","article-title":"Efficacy of infliximab for induction and maintenance of remission in intestinal Behcet\u2019s disease.","volume":"14","author":"Naganuma","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"R5-7-20210129","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.2169\/internalmedicine.52.0589","article-title":"Efficacy of infliximab in patients with intestinal Behcet\u2019s disease refractory to conventional medication.","volume":"52","author":"Kinoshita","year":"2013","journal-title":"Intern Med"},{"key":"R6-7-20210129","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s00535-013-0872-4","article-title":"The 2nd edition of consensus statements for the diagnosis and management of intestinal Behcet\u2019s disease: indication of anti-TNFalpha monoclonal antibodies.","volume":"49","author":"Hisamatsu","year":"2014","journal-title":"J Gastroenterol"},{"key":"R7-7-20210129","doi-asserted-by":"crossref","first-page":"e3863","DOI":"10.1097\/MD.0000000000003863","article-title":"Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study.","volume":"95","author":"Hibi","year":"2016","journal-title":"Medicine (Baltimore"},{"key":"R8-7-20210129","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1568-9972(03)00048-X","article-title":"The biology of TNF blockade.","volume":"2","author":"Suryaprasad","year":"2003","journal-title":"Autoimmun Rev"},{"key":"R9-7-20210129","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/art.10524","article-title":"Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study.","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R10-7-20210129","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1128\/CMR.00034-13","article-title":"Gamma interferon release assays for detection of Mycobacterium tuberculosis infection.","volume":"27","author":"Pai","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"R11-7-20210129","doi-asserted-by":"crossref","first-page":"177","DOI":"10.7326\/0003-4819-149-3-200808050-00241","article-title":"Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update.","volume":"149","author":"Pai","year":"2008","journal-title":"Ann Intern Med"},{"key":"R12-7-20210129","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1136\/ard.2007.069799","article-title":"Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy.","volume":"66","author":"Sellam","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R13-7-20210129","first-page":"776","article-title":"Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population.","volume":"35","author":"Ponce de Leon","year":"2008","journal-title":"J Rheumatol"},{"key":"R14-7-20210129","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/ard.2007.070789","article-title":"Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay.","volume":"67","author":"Matulis","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R16-7-20210129","first-page":"385","article-title":"Behcet\u2019s disease and streptococcal infection.","volume":"30","author":"Namba","year":"1986","journal-title":"Jpn J Ophthalmol"},{"key":"R18-7-20210129","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1183\/13993003.01245-2015","article-title":"Management of latent mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries.","volume":"46","author":"Getahun","year":"2015","journal-title":"Eur Respir J"},{"key":"R19-7-20210129","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S1473-3099(17)30402-4","article-title":"Incidence of active tuberculosis in individuals with latent tuberculosis infection in rural China: follow-up results of a population-based, multicentre, prospective cohort study.","volume":"17","author":"Gao","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"R20-7-20210129","doi-asserted-by":"crossref","first-page":"e0119260","DOI":"10.1371\/journal.pone.0119260","article-title":"QuantiFERON-TB Gold In-Tube assay for screening arthritis patients for latent tuberculosis infection before starting anti-tumor necrosis factor treatment.","volume":"10","author":"Lee","year":"2015","journal-title":"PLoS One"},{"key":"R21-7-20210129","doi-asserted-by":"crossref","first-page":"e0119897","DOI":"10.1371\/journal.pone.0119897","article-title":"Adverse events of anti-tumor necrosis factor alpha therapy in ankylosing spondylitis.","volume":"10","author":"Tong","year":"2015","journal-title":"PLoS One"},{"key":"R22-7-20210129","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1159\/000434684","article-title":"Factors affecting the tuberculosis risk in patients receiving anti-tumor necrosis factor-alpha treatment.","volume":"90","author":"Borekci","year":"2015","journal-title":"Respiration"},{"key":"R23-7-20210129","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1136\/ard.2008.087957","article-title":"Management of Behcet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behcet disease.","volume":"68","author":"Hatemi","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R24-7-20210129","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.semarthrit.2010.09.002","article-title":"Anti-TNF agents for Behcet\u2019s disease: analysis of published data on 369 patients.","volume":"41","author":"Arida","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"R25-7-20210129","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/0092-8674(89)90676-4","article-title":"The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection.","volume":"56","author":"Kindler","year":"1989","journal-title":"Cell"},{"key":"R26-7-20210129","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/rheumatology\/kem034","article-title":"Anti-TNF therapy in the management of Behcet\u2019s disease--review and basis for recommendations.","volume":"46","author":"Sfikakis","year":"2007","journal-title":"Rheumatology (Oxford"},{"key":"R27-7-20210129","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1097\/00007890-200211270-00006","article-title":"Diagnosis and treatment of latent tuberculosis infection in liver transplant recipients in an endemic area.","volume":"74","author":"Benito","year":"2002","journal-title":"Transplantation"},{"key":"R28-7-20210129","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1136\/annrheumdis-2011-200408","article-title":"Influence of replacing tuberculin skin test with ex vivo interferon gamma release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy.","volume":"71","author":"Mariette","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R29-7-20210129","doi-asserted-by":"crossref","first-page":"e0141033","DOI":"10.1371\/journal.pone.0141033","article-title":"The significance of sensitive interferon gamma release assays for diagnosis of latent tuberculosis infection in patients receiving tumor necrosis factor-alpha antagonist therapy.","volume":"10","author":"Jung","year":"2015","journal-title":"PLoS One"},{"key":"R30-7-20210129","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1086\/381754","article-title":"Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy.","volume":"38","author":"Carrara","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R31-7-20210129","doi-asserted-by":"crossref","first-page":"e5187","DOI":"10.1371\/journal.pone.0005187","article-title":"In vivo and in vitro effects of antituberculosis treatment on mycobacterial interferon-gamma T cell response.","volume":"4","author":"Sauzullo","year":"2009","journal-title":"PLoS One"},{"key":"R32-7-20210129","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.4049\/jimmunol.151.4.2273","article-title":"T cell epitope expression of mycobacterial and homologous human 65-kilodalton heat shock protein peptides in short term cell lines from patients with Behcet\u2019s disease.","volume":"151","author":"Pervin","year":"1993","journal-title":"J Immunol"}],"container-title":["Journal of the Chinese Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JCMA.0000000000000071","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T21:32:56Z","timestamp":1694727176000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/02118582-201905000-00007"}},"subtitle":["A retrospective study"],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/jcma.0000000000000071","relation":{},"ISSN":["1726-4901"],"issn-type":[{"value":"1726-4901","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]}}}